Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Thirteen new option listings and two option delistings on November 18th » 08:30
11/18/20
11/18
08:30
11/18/20
08:30
CBAT

CBAK Energy Technology

$9.70 /

-1.5 (-13.39%)

, DEEP

Superior Offshore

$26.01 /

+0.24 (+0.93%)

, FPH

Five Point Holdings

$4.72 /

-0.12 (-2.48%)

, HOMZ

HOme Products International

$31.55 /

+0.3158 (+1.01%)

, IMVT

Immunovant

$52.67 /

+0.06 (+0.11%)

, MP

Genset SA

$14.35 /

+0.36 (+2.57%)

, NETL

NetLogic

$24.09 /

+ (+0.00%)

, PAE

PAE

$9.66 /

+0.21 (+2.22%)

, SRRK

Scholar Rock

$39.42 /

+1.23 (+3.22%)

, FVAC

Fortress Value Acquisition

$0.00 /

+ (+0.00%)

, MYOK

MyoKardia

$224.91 /

+ (+0.00%)

New option listings for…

New option listings for November 18th include CBAK Energy Technology Inc (CBAT), United States Copper Index Fund (CPER), Roundhill Acquirers Deep Value ETF (DEEP), EMQQ The Emerging Markets Internet and Ecommerce ETF (EMQQ), Five Point Holdings (FPH), Hoya Capital Housing ETF (HOMZ), iShares Bb Rated Corporate Bond ETF (HYBB), Immunovant Inc (IMVT), MP Materials Corp (MP), Netlease Corporate Real Estate ETF (NETL), PAE Incorporated (Class A Stock) (PAE), Scholar Rock Holdings Corporation (SRRK), and Northshore Global Uranium Mining ETF (URNM). Option delistings effective November 18th include Fortress Value Acquisition Corp (Class A Stock) (FVAC) and MyoKardia Inc (MYOK).

ShowHide Related Items >><<
SRRK Scholar Rock
$39.42 /

+1.23 (+3.22%)

PAE PAE
$9.66 /

+0.21 (+2.22%)

MYOK MyoKardia
$224.91 /

+ (+0.00%)

IMVT Immunovant
$52.67 /

+0.06 (+0.11%)

FVAC Fortress Value Acquisition
$0.00 /

+ (+0.00%)

CBAT CBAK Energy Technology
$9.70 /

-1.5 (-13.39%)

CBAT CBAK Energy Technology
$9.70 /

-1.5 (-13.39%)

DEEP Superior Offshore
$26.01 /

+0.24 (+0.93%)

FPH Five Point Holdings
$4.72 /

-0.12 (-2.48%)

HOMZ HOme Products International
$31.55 /

+0.3158 (+1.01%)

IMVT Immunovant
$52.67 /

+0.06 (+0.11%)

11/13/20 Truist
Immunovant price target raised to $62 from $52 at Truist
11/13/20 SVB Leerink
Immunovant price target raised to $52 from $39 at SVB Leerink
11/13/20 Baird
Immunovant price target raised to $64 from $47 at Baird
11/13/20 H.C. Wainwright
Immunovant price target raised to $54 from $40 at H.C. Wainwright
MP Genset SA
$14.35 /

+0.36 (+2.57%)

NETL NetLogic
$24.09 /

+ (+0.00%)

PAE PAE
$9.66 /

+0.21 (+2.22%)

06/16/20
Fly Intel: Top five analyst initiations
06/16/20 Raymond James
PAE initiated with an Outperform at Raymond James
06/15/20 Raymond James
PAE initiated with an Outperform at Raymond James
05/15/20
Fly Intel: Top five analyst initiations
SRRK Scholar Rock
$39.42 /

+1.23 (+3.22%)

11/10/20 Wedbush
Scholar Rock price target raised to $47 from $33 at Wedbush
10/28/20 BMO Capital
Scholar Rock price target raised to $52 from $33 at BMO Capital
10/27/20 Baird
Scholar Rock price target raised to $39 from $35 at Baird
03/12/20
Fly Intel: Top five analyst initiations
FVAC Fortress Value Acquisition
$0.00 /

+ (+0.00%)

MYOK MyoKardia
$224.91 /

+ (+0.00%)

10/08/20 Piper Sandler
Piper cuts Cytokinetics target to $25, but buyer on weakness after trial data
10/06/20 Cowen
MyoKardia downgraded to Market Perform from Outperform at Cowen
10/06/20 Wedbush
MyoKardia downgraded to Neutral from Outperform at Wedbush
10/06/20 Morgan Stanley
MyoKardia downgraded to Equal Weight from Overweight at Morgan Stanley
SRRK Scholar Rock
$39.42 /

+1.23 (+3.22%)

PAE PAE
$9.66 /

+0.21 (+2.22%)

MYOK MyoKardia
$224.91 /

+ (+0.00%)

IMVT Immunovant
$52.67 /

+0.06 (+0.11%)

  • 29
    Oct
  • 02
    Sep
  • 13
    May
  • 14
    Apr
MYOK MyoKardia
$224.91 /

+ (+0.00%)

SRRK Scholar Rock
$39.42 /

+1.23 (+3.22%)

MYOK MyoKardia
$224.91 /

+ (+0.00%)

IMVT Immunovant
$52.67 /

+0.06 (+0.11%)

CBAT CBAK Energy Technology
$9.70 /

-1.5 (-13.39%)

MYOK MyoKardia
$224.91 /

+ (+0.00%)

FVAC Fortress Value Acquisition
$0.00 /

+ (+0.00%)

Recommendations
Scholar Rock price target raised to $47 from $33 at Wedbush » 08:48
11/10/20
11/10
08:48
11/10/20
08:48
SRRK

Scholar Rock

$41.65 /

-0.57 (-1.35%)

Wedbush analyst David…

Wedbush analyst David Nierengarten raised the firm's price target on Scholar Rock to $47 from $33 and keeps an Outperform rating on the shares. The analyst notes that the company reported Q3 earnings and recently reported positive interim data from the Phase 2 TOPAZ study evaluating apitegromab in patients with SMA Types II and III that showed "encouraging" motor function improvements from baseline. Nierengarten believes the early data support apitegromab's benefit, and its potential to improve over time. Topline 12-month data are slated for Q2 2021 and should give a better measure of true benefit.

ShowHide Related Items >><<
SRRK Scholar Rock
$41.65 /

-0.57 (-1.35%)

SRRK Scholar Rock
$41.65 /

-0.57 (-1.35%)

10/28/20 BMO Capital
Scholar Rock price target raised to $52 from $33 at BMO Capital
10/27/20 Baird
Scholar Rock price target raised to $39 from $35 at Baird
03/12/20
Fly Intel: Top five analyst initiations
03/11/20 Baird
Scholar Rock initiated with an Outperform at Baird
SRRK Scholar Rock
$41.65 /

-0.57 (-1.35%)

  • 29
    Oct
SRRK Scholar Rock
$41.65 /

-0.57 (-1.35%)

Earnings
Scholar Rock reports Q3 EPS (79c), consensus (55c) » 08:03
11/09/20
11/09
08:03
11/09/20
08:03
SRRK

Scholar Rock

$42.22 /

-2.19 (-4.93%)

Reports Q3 revenue $3M,…

Reports Q3 revenue $3M, consensus $7.62M.

ShowHide Related Items >><<
SRRK Scholar Rock
$42.22 /

-2.19 (-4.93%)

SRRK Scholar Rock
$42.22 /

-2.19 (-4.93%)

10/28/20 BMO Capital
Scholar Rock price target raised to $52 from $33 at BMO Capital
10/27/20 Baird
Scholar Rock price target raised to $39 from $35 at Baird
03/12/20
Fly Intel: Top five analyst initiations
03/11/20 Baird
Scholar Rock initiated with an Outperform at Baird
SRRK Scholar Rock
$42.22 /

-2.19 (-4.93%)

  • 29
    Oct
SRRK Scholar Rock
$42.22 /

-2.19 (-4.93%)

Over a month ago
Syndicate
Scholar Rock 2.949M share Spot Secondary priced at $39.00 » 06:19
10/29/20
10/29
06:19
10/29/20
06:19
SRRK

Scholar Rock

$43.50 /

+13.34 (+44.23%)

The deal size was…

The deal size was increased to $200M in common stock from $150M in common stock. JPMorgan, Jefferies and Credit Suisse acted as joint book running managers for the offering.

ShowHide Related Items >><<
SRRK Scholar Rock
$43.50 /

+13.34 (+44.23%)

SRRK Scholar Rock
$43.50 /

+13.34 (+44.23%)

10/28/20 BMO Capital
Scholar Rock price target raised to $52 from $33 at BMO Capital
10/27/20 Baird
Scholar Rock price target raised to $39 from $35 at Baird
03/12/20
Fly Intel: Top five analyst initiations
03/11/20 Baird
Scholar Rock initiated with an Outperform at Baird
SRRK Scholar Rock
$43.50 /

+13.34 (+44.23%)

  • 29
    Oct
SRRK Scholar Rock
$43.50 /

+13.34 (+44.23%)

Recommendations
Scholar Rock price target raised to $52 from $33 at BMO Capital » 08:53
10/28/20
10/28
08:53
10/28/20
08:53
SRRK

Scholar Rock

$30.16 /

+16.42 (+119.51%)

BMO Capital analyst Do…

BMO Capital analyst Do Kim raised the firm's price target on Scholar Rock to $52 from $33 and keeps an Outperform rating on the shares. The analyst cites the company's "positive" interim phase 2 data of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy and believes that the 6-month outcomes for all cohorts "comfortably beat motor function and responder rate hurdles". Kim also increases his probability of success for the program to 50% from 33% following yesterday's update.

ShowHide Related Items >><<
SRRK Scholar Rock
$30.16 /

+16.42 (+119.51%)

SRRK Scholar Rock
$30.16 /

+16.42 (+119.51%)

10/27/20 Baird
Scholar Rock price target raised to $39 from $35 at Baird
03/12/20
Fly Intel: Top five analyst initiations
03/11/20 Baird
Scholar Rock initiated with an Outperform at Baird
SRRK Scholar Rock
$30.16 /

+16.42 (+119.51%)

  • 29
    Oct
SRRK Scholar Rock
$30.16 /

+16.42 (+119.51%)

On The Fly
Fly Intel: After-Hours Movers » 18:11
10/27/20
10/27
18:11
10/27/20
18:11
CYH

Community Health

$4.39 /

-0.4 (-8.35%)

, FSLR

First Solar

$82.38 /

-1.33 (-1.59%)

, SKY

Skyline

$24.76 /

-0.29 (-1.16%)

, MSTR

MicroStrategy

$175.38 /

+0.29 (+0.17%)

, RRR

Red Rock Resorts

$18.78 /

-0.78 (-3.99%)

, FEYE

FireEye

$14.09 /

-0.06 (-0.42%)

, OKE

Oneok

$29.28 /

-0.25 (-0.85%)

, JNPR

Juniper

$21.84 /

-0.06 (-0.27%)

, MKSI

MKS Instruments

$109.70 /

-0.06 (-0.05%)

, FISV

Fiserv

$96.72 /

-1.75 (-1.78%)

, CB

Chubb

$123.51 /

-2.5 (-1.98%)

, SWI

SolarWinds

$21.61 /

+0.17 (+0.79%)

, TENB

Tenable Holdings

$37.16 /

+0.59 (+1.61%)

, DENN

Denny's

$10.62 /

+0.28 (+2.71%)

, SRRK

Scholar Rock

$30.16 /

+16.42 (+119.51%)

, SUM

Summit Materials

$18.84 /

+0.01 (+0.05%)

, BGFV

Big 5 Sporting

$8.11 /

+0.15 (+1.88%)

, AKAM

Akamai

$106.81 /

+0.85 (+0.80%)

, CHRW

C.H. Robinson

$100.00 /

+0.41 (+0.41%)

, TWOU

2U

$37.32 /

+0.87 (+2.39%)

, UVE

Universal Insurance

$13.47 /

-0.625 (-4.44%)

, ZYXI

Zynex

$14.28 /

+0.13 (+0.92%)

, MTDR

Matador

$8.16 /

-0.02 (-0.24%)

Check out this evening's…

ShowHide Related Items >><<
ZYXI Zynex
$14.28 /

+0.13 (+0.92%)

UVE Universal Insurance
$13.47 /

-0.625 (-4.44%)

TWOU 2U
$37.32 /

+0.87 (+2.39%)

TENB Tenable Holdings
$37.16 /

+0.59 (+1.61%)

SWI SolarWinds
$21.61 /

+0.17 (+0.79%)

SUM Summit Materials
$18.84 /

+0.01 (+0.05%)

SRRK Scholar Rock
$30.16 /

+16.42 (+119.51%)

RRR Red Rock Resorts
$18.78 /

-0.78 (-3.99%)

OKE Oneok
$29.28 /

-0.25 (-0.85%)

MTDR Matador
$8.16 /

-0.02 (-0.24%)

MSTR MicroStrategy
$175.38 /

+0.29 (+0.17%)

MKSI MKS Instruments
$109.70 /

-0.06 (-0.05%)

JNPR Juniper
$21.84 /

-0.06 (-0.27%)

FSLR First Solar
$82.38 /

-1.33 (-1.59%)

FISV Fiserv
$96.72 /

-1.75 (-1.78%)

FEYE FireEye
$14.09 /

-0.06 (-0.42%)

DENN Denny's
$10.62 /

+0.28 (+2.71%)

CYH Community Health
$4.39 /

-0.4 (-8.35%)

CHRW C.H. Robinson
$100.00 /

+0.41 (+0.41%)

CB Chubb
$123.51 /

-2.5 (-1.98%)

BGFV Big 5 Sporting
$8.11 /

+0.15 (+1.88%)

AKAM Akamai
$106.81 /

+0.85 (+0.80%)

CYH Community Health
$4.39 /

-0.4 (-8.35%)

06/11/20 Citi
Community Health price target raised to $3.50 from $3.00 at Citi
03/26/20 JPMorgan
Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
02/24/20 RBC Capital
Community Health price target raised to $8 from $4 at RBC Capital
02/20/20 Raymond James
Community Health upgraded at Raymond James as near-term pressures limited
FSLR First Solar
$82.38 /

-1.33 (-1.59%)

10/26/20 Credit Suisse
First Solar downgraded to Underperform at Credit Suisse
10/26/20 Roth Capital
First Solar upgraded to Buy at Roth Capital on policy drivers
10/26/20 Roth Capital
First Solar upgraded to Buy from Neutral at Roth Capital
10/26/20 Credit Suisse
First Solar downgraded to Underperform from Neutral at Credit Suisse
SKY Skyline
$24.76 /

-0.29 (-1.16%)

05/21/20 Truist
Skyline upgraded to Buy from Hold at SunTrust
05/20/20 Truist
SunTrust upgrades Skyline to Buy ahead of today's earnings report
05/20/20 Truist
Skyline upgraded to Buy from Hold at SunTrust
04/07/20 RBC Capital
Skyline downgraded to Sector Perform from Outperform at RBC Capital
MSTR MicroStrategy
$175.38 /

+0.29 (+0.17%)

10/30/19 Citi
MicroStrategy's execution challenges resurface, says Citi
RRR Red Rock Resorts
$18.78 /

-0.78 (-3.99%)

10/14/20 JPMorgan
Red Rock Resorts price target raised to $23 from $21 at JPMorgan
09/14/20 Goldman Sachs
Red Rock Resorts price target raised to $20 from $15 at Goldman Sachs
09/14/20 Goldman Sachs
MGM Resorts downgraded to Sell from Neutral at Goldman Sachs
09/09/20 JPMorgan
Red Rock Resorts price target raised to $21 from $17 at JPMorgan
FEYE FireEye
$14.09 /

-0.06 (-0.42%)

10/14/20 Baird
FireEye added as positive Fresh Pick ahead of earnings at Baird
07/29/20 JPMorgan
FireEye price target raised to $18 from $15 at JPMorgan
07/29/20 Mizuho
FireEye price target raised to $17 from $15 at Mizuho
04/13/20 BMO Capital
FireEye price target lowered to $12.50 from $17 at BMO Capital
OKE Oneok
$29.28 /

-0.25 (-0.85%)

10/14/20 Goldman Sachs
Oneok downgraded to Sell from Neutral at Goldman Sachs
10/05/20 Wells Fargo
Oneok upgraded to Overweight from Equal Weight at Wells Fargo
10/05/20 Wells Fargo
Oneok upgraded to Overweight from Equal Weight at Wells Fargo
09/29/20
Oneok upgraded to Buy at UBS on improving volume outlook
JNPR Juniper
$21.84 /

-0.06 (-0.27%)

09/22/20 UBS
Juniper assumed with a Neutral at UBS
09/11/20 Raymond James
Juniper price target raised to $28 from $27 at Raymond James
09/04/20 Morgan Stanley
Ciena price target lowered to $46 from $50 at Morgan Stanley
07/24/20 Wolfe Research
Juniper initiated with a Peer Perform at Wolfe Research
MKSI MKS Instruments
$109.70 /

-0.06 (-0.05%)

10/14/20 Stifel
Stifel remains bullish on MKS, highlights exposure to flexible PCB market
09/11/20 Berenberg
MKS Instruments initiated with a Buy at Berenberg
07/31/20 Deutsche Bank
MKS Instruments price target raised to $145 from $130 at Deutsche Bank
07/28/20 Needham
MKS Instruments price target raised to $135 from $125 at Needham
FISV Fiserv
$96.72 /

-1.75 (-1.78%)

10/20/20 JPMorgan
Fiserv price target lowered to $119 from $126 at JPMorgan
10/06/20 Credit Suisse
Fiserv upgraded to Outperform at Credit Suisse on improving mix and valuation
10/06/20 Credit Suisse
Fiserv upgraded to Outperform from Neutral at Credit Suisse
09/22/20
Top five analyst initiations
CB Chubb
$123.51 /

-2.5 (-1.98%)

10/12/20 JPMorgan
Chubb upgraded to Overweight from Neutral at JPMorgan
10/12/20 JPMorgan
Travelers downgraded to Underweight from Neutral at JPMorgan
07/16/20 Evercore ISI
Chubb upgraded to Outperform from In Line at Evercore ISI
07/07/20 Wells Fargo
Chubb price target raised to $150 from $142 at Wells Fargo
SWI SolarWinds
$21.61 /

+0.17 (+0.79%)

10/07/20 Berenberg
SolarWinds initiated with a Buy at Berenberg
08/07/20 Jefferies
SolarWinds price target raised to $22 from $19 at Jefferies
06/24/20 Goldman Sachs
SolarWinds price target raised to $18 from $16 at Goldman Sachs
04/23/20 Credit Suisse
SolarWinds downgraded to Neutral from Outperform at Credit Suisse
TENB Tenable Holdings
$37.16 /

+0.59 (+1.61%)

10/01/20 Monness Crespi
Tenable Holdings price target raised to $44 from $38 at Monness Crespi
09/28/20 Piper Sandler
Tenable Holdings initiated with an Overweight at Piper Sandler
09/25/20 DA Davidson
Tenable Holdings initiated with a Buy at DA Davidson
07/29/20 JPMorgan
Tenable Holdings price target raised to $45 from $31 at JPMorgan
DENN Denny's
$10.62 /

+0.28 (+2.71%)

08/27/20 Stephens
Denny's catalyst will be easing of COVID restrictions, says Stephens
07/13/20
Fly Intel: Top five analyst downgrades
07/13/20 Stephens
Denny's downgraded to Equal Weight from Overweight at Stephens
06/17/20 Truist
Denny's price target raised to $15 from $12 at SunTrust
SRRK Scholar Rock
$30.16 /

+16.42 (+119.51%)

10/27/20 Baird
Scholar Rock price target raised to $39 from $35 at Baird
03/12/20
Fly Intel: Top five analyst initiations
03/11/20 Baird
Scholar Rock initiated with an Outperform at Baird
SUM Summit Materials
$18.84 /

+0.01 (+0.05%)

08/06/20 JPMorgan
Summit Materials upgraded to Overweight with $20 target at JPMorgan
08/06/20 JPMorgan
Summit Materials upgraded to Overweight from Neutral at JPMorgan
07/23/20
Fly Intel: Top five analyst upgrades
07/23/20 Loop Capital
Summit Materials upgraded to Buy from Hold at Loop Capital
BGFV Big 5 Sporting
$8.11 /

+0.15 (+1.88%)

10/21/20
Fly Intel: Top five analyst initiations
10/21/20 Lake Street
Big 5 Sporting initiated with a Buy at Lake Street
AKAM Akamai
$106.81 /

+0.85 (+0.80%)

10/15/20 DA Davidson
Fastly price target lowered to $105 from $115 at DA Davidson
10/15/20 Piper Sandler
Piper says buy Akamai, Cloudflare on Fastly related selloff
10/08/20 FBN Securities
Cloudflare initiated with an Outperform at FBN Securities
07/29/20 Craig-Hallum
Akamai price target raised to $130 from $120 at Craig-Hallum
CHRW C.H. Robinson
$100.00 /

+0.41 (+0.41%)

10/16/20 Barclays
C.H. Robinson price target raised to $115 from $95 at Barclays
09/23/20 Wells Fargo
C.H. Robinson initiated with an Underweight at Wells Fargo
08/17/20 Baird
C.H. Robinson downgraded to Neutral at Baird
08/17/20 Baird
C.H. Robinson downgraded to Neutral from Outperform at Baird
TWOU 2U
$37.32 /

+0.87 (+2.39%)

10/01/20 DA Davidson
2U price target lowered to $34 from $44 at DA Davidson
09/24/20 KeyBanc
Initial enrollment data from NSCRC 'positive' for Chegg, says KeyBanc
08/03/20 BMO Capital
2U price target raised to $54 from $48 at BMO Capital
07/31/20 Barrington
2U price target raised to $55 from $50 at Barrington
UVE Universal Insurance
$13.47 /

-0.625 (-4.44%)

05/28/20 Piper Sandler
Universal Insurance initiated with a Neutral at Piper Sandler
11/03/19 Keefe Bruyette
Universal Insurance downgraded to Underperform at Keefe Bruyette
ZYXI Zynex
$14.28 /

+0.13 (+0.92%)

10/13/20 B. Riley Securities
Zynex selloff yesterday 'significant overreaction,' says B. Riley Securities
10/12/20 Piper Sandler
Piper sees Zynex preliminary results miss as only near-term 'bump in the road'
09/14/20 H.C. Wainwright
Zynex upgraded to Buy from Neutral at H.C. Wainwright
09/09/20 Northland
Zynex upgraded to Outperform from Market Perform at Northland
MTDR Matador
$8.16 /

-0.02 (-0.24%)

09/22/20 Truist
Matador upgraded to Buy from Hold at Truist
09/22/20 Truist
Matador upgraded to Buy from Hold at Truist
09/14/20 Wells Fargo
Matador upgraded to Overweight from Equal Weight at Wells Fargo
07/29/20 Northland
Matador guidance seems conservative after 'big beat' in Q2, says Northland
ZYXI Zynex
$14.28 /

+0.13 (+0.92%)

UVE Universal Insurance
$13.47 /

-0.625 (-4.44%)

TWOU 2U
$37.32 /

+0.87 (+2.39%)

TENB Tenable Holdings
$37.16 /

+0.59 (+1.61%)

SWI SolarWinds
$21.61 /

+0.17 (+0.79%)

SUM Summit Materials
$18.84 /

+0.01 (+0.05%)

SRRK Scholar Rock
$30.16 /

+16.42 (+119.51%)

SKY Skyline
$24.76 /

-0.29 (-1.16%)

RRR Red Rock Resorts
$18.78 /

-0.78 (-3.99%)

OKE Oneok
$29.28 /

-0.25 (-0.85%)

MTDR Matador
$8.16 /

-0.02 (-0.24%)

MSTR MicroStrategy
$175.38 /

+0.29 (+0.17%)

MKSI MKS Instruments
$109.70 /

-0.06 (-0.05%)

JNPR Juniper
$21.84 /

-0.06 (-0.27%)

FSLR First Solar
$82.38 /

-1.33 (-1.59%)

FISV Fiserv
$96.72 /

-1.75 (-1.78%)

FEYE FireEye
$14.09 /

-0.06 (-0.42%)

DENN Denny's
$10.62 /

+0.28 (+2.71%)

CYH Community Health
$4.39 /

-0.4 (-8.35%)

CHRW C.H. Robinson
$100.00 /

+0.41 (+0.41%)

CB Chubb
$123.51 /

-2.5 (-1.98%)

BGFV Big 5 Sporting
$8.11 /

+0.15 (+1.88%)

AKAM Akamai
$106.81 /

+0.85 (+0.80%)

  • 29
    Oct
  • 17
    Sep
  • 06
    Aug
  • 31
    Jul
  • 15
    Jul
  • 01
    Jul
  • 12
    Jun
MTDR Matador
$8.16 /

-0.02 (-0.24%)

MKSI MKS Instruments
$109.70 /

-0.06 (-0.05%)

JNPR Juniper
$21.84 /

-0.06 (-0.27%)

FEYE FireEye
$14.09 /

-0.06 (-0.42%)

DENN Denny's
$10.62 /

+0.28 (+2.71%)

CYH Community Health
$4.39 /

-0.4 (-8.35%)

CB Chubb
$123.51 /

-2.5 (-1.98%)

ZYXI Zynex
$14.28 /

+0.13 (+0.92%)

TWOU 2U
$37.32 /

+0.87 (+2.39%)

TENB Tenable Holdings
$37.16 /

+0.59 (+1.61%)

SUM Summit Materials
$18.84 /

+0.01 (+0.05%)

SKY Skyline
$24.76 /

-0.29 (-1.16%)

RRR Red Rock Resorts
$18.78 /

-0.78 (-3.99%)

OKE Oneok
$29.28 /

-0.25 (-0.85%)

MTDR Matador
$8.16 /

-0.02 (-0.24%)

MSTR MicroStrategy
$175.38 /

+0.29 (+0.17%)

JNPR Juniper
$21.84 /

-0.06 (-0.27%)

FSLR First Solar
$82.38 /

-1.33 (-1.59%)

FISV Fiserv
$96.72 /

-1.75 (-1.78%)

FEYE FireEye
$14.09 /

-0.06 (-0.42%)

DENN Denny's
$10.62 /

+0.28 (+2.71%)

CYH Community Health
$4.39 /

-0.4 (-8.35%)

BGFV Big 5 Sporting
$8.11 /

+0.15 (+1.88%)

AKAM Akamai
$106.81 /

+0.85 (+0.80%)

TWOU 2U
$37.32 /

+0.87 (+2.39%)

RRR Red Rock Resorts
$18.78 /

-0.78 (-3.99%)

OKE Oneok
$29.28 /

-0.25 (-0.85%)

JNPR Juniper
$21.84 /

-0.06 (-0.27%)

FSLR First Solar
$82.38 /

-1.33 (-1.59%)

FISV Fiserv
$96.72 /

-1.75 (-1.78%)

FEYE FireEye
$14.09 /

-0.06 (-0.42%)

DENN Denny's
$10.62 /

+0.28 (+2.71%)

CYH Community Health
$4.39 /

-0.4 (-8.35%)

CHRW C.H. Robinson
$100.00 /

+0.41 (+0.41%)

BGFV Big 5 Sporting
$8.11 /

+0.15 (+1.88%)

AKAM Akamai
$106.81 /

+0.85 (+0.80%)

Hot Stocks
Scholar Rock up 20% to $35.90 after offering, proceeds used in advancing trial » 17:59
10/27/20
10/27
17:59
10/27/20
17:59
SRRK

Scholar Rock

$30.16 /

+16.42 (+119.51%)

Shares of Scholar Rock…

Shares of Scholar Rock are up 20% at $35.90 after the company announced an equity offering of $150M, stating that it "intends to use the net proceeds from the offering to advance SRK-015 in Spinal Muscular Atrophy, including costs associated with preparing for and executing clinical trials - including a Phase 3 clinical trial - SRK-181 in cancer immunotherapy, development of its preclinical and discovery programs, as well as for working capital and other general corporate purposes.

ShowHide Related Items >><<
SRRK Scholar Rock
$30.16 /

+16.42 (+119.51%)

SRRK Scholar Rock
$30.16 /

+16.42 (+119.51%)

10/27/20 Baird
Scholar Rock price target raised to $39 from $35 at Baird
03/12/20
Fly Intel: Top five analyst initiations
03/11/20 Baird
Scholar Rock initiated with an Outperform at Baird
SRRK Scholar Rock
$30.16 /

+16.42 (+119.51%)

  • 29
    Oct
Syndicate
Scholar Rock files to sell $150M in common stock » 16:18
10/27/20
10/27
16:18
10/27/20
16:18
SRRK

Scholar Rock

$30.16 /

+16.42 (+119.51%)

J.P. Morgan Securities…

J.P. Morgan Securities LLC, Jefferies LLC and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering. BMO Capital Markets Corp. is acting as lead manager for the offering.

ShowHide Related Items >><<
SRRK Scholar Rock
$30.16 /

+16.42 (+119.51%)

SRRK Scholar Rock
$30.16 /

+16.42 (+119.51%)

10/27/20 Baird
Scholar Rock price target raised to $39 from $35 at Baird
03/12/20
Fly Intel: Top five analyst initiations
03/11/20 Baird
Scholar Rock initiated with an Outperform at Baird
SRRK Scholar Rock
$30.16 /

+16.42 (+119.51%)

Recommendations
Scholar Rock price target raised to $39 from $35 at Baird » 10:48
10/27/20
10/27
10:48
10/27/20
10:48
SRRK

Scholar Rock

$23.55 /

+9.81 (+71.40%)

Baird analyst Madhu Kumar…

Baird analyst Madhu Kumar raised the firm's price target on Scholar Rock to $39 from $35 and keeps an Outperform rating on the shares. The analyst notes that Scholar Rock has announced 6-month interim data from the Phase 2 TOPAZ trial of antipromyostatin mAb SRK-015 in spinal muscular atrophy types 2/3. Overall, he was pleased by the early clinical POC shown in all cohorts of TOPAZ, especially the dose-dependent improvement in motor function observed in cohort 3. Kumar reiterates the stock status as a Fresh Pick.

ShowHide Related Items >><<
SRRK Scholar Rock
$23.55 /

+9.81 (+71.40%)

SRRK Scholar Rock
$23.55 /

+9.81 (+71.40%)

03/12/20
Fly Intel: Top five analyst initiations
03/11/20 Baird
Scholar Rock initiated with an Outperform at Baird
SRRK Scholar Rock
$23.55 /

+9.81 (+71.40%)

Hot Stocks
Scholar Rock announces six-month interim analysis from TOPAZ Phase 2 » 07:18
10/27/20
10/27
07:18
10/27/20
07:18
SRRK

Scholar Rock

$13.74 /

-0.47 (-3.31%)

Scholar Rock announced…

Scholar Rock announced positive six-month interim analysis results from the TOPAZ Phase 2 clinical trial. Treatment with SRK-015 led to improvements in Hammersmith scale scores (primary efficacy endpoint) in all three cohorts of patients with Type 2 and Type 3 Spinal Muscular Atrophy . Dose response in the primary efficacy endpoint was observed across all evaluated timepoints in the double-blind, randomized portion of the trial . The high-dose arm of Cohort 3 attained a 5.6 point mean improvement from baseline in the Hammersmith Functional Motor Scale Expanded as compared to the low dose arm, which attained a 2.4 point mean improvement at the six-month interim analysis timepoint. No safety signals were identified from the interim analysis. "These interim results are important because they demonstrate the potential of this muscle-directed approach to improve motor function of individuals with Type 2 and Type 3 SMA," said Thomas Crawford, M.D., Professor of Neurology at the Johns Hopkins University School of Medicine and Lead Investigator of the TOPAZ trial. "In the last few years, we've celebrated the remarkable success in treating SMA with SMN-upregulating approaches that stabilize against neurodegeneration. These findings highlight the potential for a whole new approach to SMA therapy, used in conjunction with the SMN-enhancing therapies, to address the persistent and significant unmet needs of individuals weakened by SMA." "This is an exciting and important step towards establishing SRK-015 as the potential first muscle-directed therapy for patients with SMA, while also providing important validation of our scientific approach of targeting the latent forms of growth factors," said Yung Chyung, M.D., Chief Medical Officer of Scholar Rock. "These interim data support the continuation of the TOPAZ trial and we look forward to engaging with regulatory authorities regarding our registrational trial plans."

ShowHide Related Items >><<
SRRK Scholar Rock
$13.74 /

-0.47 (-3.31%)

SRRK Scholar Rock
$13.74 /

-0.47 (-3.31%)

03/12/20
Fly Intel: Top five analyst initiations
03/11/20 Baird
Scholar Rock initiated with an Outperform at Baird
SRRK Scholar Rock
$13.74 /

-0.47 (-3.31%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.